Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 12, 2012, Pages 2218-2224

  D'Haens, Geert ^a,b   Ferrante, Marc ^c   Vermeire, Severine ^c   Baert, Filip ^d   Noman, Maja ^c   Moortgat, Liesbeth ^d   Geens, Patricia ^b   Iwens, Doreen ^b   Aerden, Isolde ^c   Van Assche, Gert ^c   Van Olmen, Gust ^b   Rutgeerts, Paul ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Imelda GI Clinical Research Centre   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Heilig Hart Ziekenhuis   (Belgium)

Author keywords

calprotectin; Crohn's disease; inflammatory bowel disease; ulcerative colitis

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINE MUCOSA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84862524860     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22917     Document Type: Article

References (34)

1. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997; 112: 1475-1481.
2. Mary JY, Modigliani R, Groupe d'Etudes Thérapeutiques des affections inflamatoires du tube digestif (GETAID). Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Gut. 1989; 30: 983-989.
3. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763-786.
4. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002; 122: 512-530.
5. D'Haens G, Fedorak R, Lémann M, et al. Endpoints for Clinical Trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1599-1604.
6. Rutgeerts P, Diamond RH, Bala M, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-413.
7. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459.
8. Rutgeerts P, D'Haens G, Van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the EXTEND trial. Gastroenterology. 2009; 136 (suppl 1): A116 [abstract].
9. Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27: 793-798.
10. Røseth AG, Schmidt PN, Fagerhol MK,. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34: 50-54.
11. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of faecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003; 49: 861-867.
12. Roseth AG, Aadland E, Grzyb K,. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39: 1017-1020.
13. Bunn SK, Bisset WM, Main MJ, et al. Faecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 14-22.
14. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364-368.
15. Sipponen T, Savilathi E, Kärkäinen P, et al. Faecal calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14: 1392-1398.
16. Daperno M, D'Haens GR, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60: 505-512.
17. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987; 317: 1625-1629.
18. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999; 45: 362-366.
19. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroentrerol. 2000; 95: 2831-2837.
20. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. Gastroenterology. 1976; 70: 439-444.
21. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet. 1980; 1: 514.
22. Sipponen T, Björkesten CG, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol. 2010; 45: 325-331.
23. D'Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007; 22: 429-437.
24. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009; 15: 1851-1858.
25. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
26. Lemann M, Colombel JF, Grimaud JC, et al. Faecal calprotectin and high-sensitivity C-reactive protein levels to assess mucosal healing in patients with Crohn's disease. A subanalysis of the STORI study. Gut. 2010; 59: A80 [abstract].
27. van Rheenen PF, Van de Vijver E, Fidler V,. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010; 341: c3369.
28. Thomas SJ, Walsh AJ, Von Herbay A, et al. How much agreement is there between histological, endoscopic and clinical assessments of remission in ulcerative colitis. Gut. 2009; 58 (Suppl 1): A101 [abstract].
29. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Lancet. 2002; 359: 1541-1549.
30. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
31. Ferrante M, Colombel JF, Sandborn WJ, et al. Evolution of endoscopic activity scores in patients with Crohn's disease under azathioprine and/or infliximab: a post-hoc analysis of the SONIC data. Gastroenterology. 2011; 140: S909 [abstract].
32. Hébuterne X, Colombel J, Bouhnik Y, et al. Endoscopic improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC trail. Gut. 2008; 57 (Suppl II): A15 [abstract].
33. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2011 [Epub ahead of print].
34. Colombel JF, Rutgeerts P, Reinisch W, et al. Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of symptomatic remission and corticosteroid-free state. Gut. 2010; 59: A411 [abstract].